EP4568969A1 — Heteroaromatic macrocyclic ether compounds
Assigned to Nuvalent Inc · Expires 2025-06-18 · 1y expired
What this patent protects
Provided herein are certain heteroaromatic macrocyclic ether compounds which are ROS1 and/or ALK inhibitors. These compounds or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, are suitable for treating, preventing or managing …
USPTO Abstract
Provided herein are certain heteroaromatic macrocyclic ether compounds which are ROS1 and/or ALK inhibitors. These compounds or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, are suitable for treating, preventing or managing cancers.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.